Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts - Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial

被引:187
作者
Vermeersch, Paul
Agostoni, Pierfrancesco
Verheye, Stefan
Van den Heuvel, Paul
Convens, Carl
Bruining, Nico
Van den Branden, Frank
Van Langenhove, Glenn
机构
[1] Antwerp Cardiovasc Inst Middelheim, AZ Middelheim, B-2020 Antwerp, Belgium
[2] Erasmus MC, Thoraxctr, Rotterdam, Netherlands
关键词
D O I
10.1016/j.jacc.2006.09.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to compare, in a randomized fashion, sirolimus-eluting stents (SES) versus bare-metal stents (BMS) in saphenous vein grafts (SVGs). BACKGROUND Sirolimus-eluting stents reduce restenosis and repeated revascularization in native coronary arteries compared with BMS. However, randomized data in SVG are absent. METHODS Patients with SVG lesions were randomized to SES or BMS. All were scheduled to undergo 6-month coronary angiography. The primary end point was 6-month angiographic in-stent late lumen loss. Secondary end points included binary angiographic restenosis, neointimal volume by intravascular ultrasound and major adverse clinical events (death, myocardial infarction, target lesion, and vessel revascularization). RESULTS A total of 75 patients with 96 lesions localized in 80 diseased SVGs were included: 38 patients received 60 SES for 47 lesions, whereas 37 patients received 54 BMS for 49 lesions. In-stent late loss was significantly reduced in SES (0.38 +/- 0.51 mm vs. 0.79 +/- 0.66 mm in BMS, p = 0.001). Binary in-stent and in-segment restenosis were reduced, 11.3% versus 30.6% (relative risk [RR] 0.37; 95% confidence interval [CI] 0.15 to 0.97, p = 0.024) and 13.6% versus 32.6% (RR 0.42; 95% CI 0.18 to 0.97, p = 0.031), respectively. Median neointimal volume was 1 mm(3) (interquartile range 0 to 13) in SES versus 24 (interquartile range 8 to 34) in BMS (p < 0.001). Target lesion and vessel revascularizarion rates were significantly reduced, 5.3% versus 21.6% (RR 0.24; 95% CI 0.05 to 1.0, p = 0.047) and 5.3% versus 27% (RR 0.19; 95% CI 0.05 to 0.83, p = 0.012), respectively. Death and myocardial infarction rates were not different. CONCLUSIONS Sirolimus-eluting stents significantly reduce late loss in SVG as opposed to BMS. This is associated with a reduction in restenosis rate and repeated target lesion and vessel revascularization procedures.
引用
收藏
页码:2423 / 2431
页数:9
相关论文
共 46 条
[1]  
Alexander JH, 2005, JAMA-J AM MED ASSOC, V294, P2446
[2]   Myocardial infarction redefined -: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Hoppe, U ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
de Werf, FV ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
EUROPEAN HEART JOURNAL, 2000, 21 (18) :1502-1513
[3]   Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries - A randomized trial [J].
Ardissino, D ;
Cavallini, C ;
Bramucci, E ;
Indolfi, C ;
Marzocchi, A ;
Manari, A ;
Angeloni, G ;
Carosio, G ;
Bonizzoni, E ;
Colusso, S ;
Repetto, M ;
Merlini, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (22) :2727-2734
[4]   Treatment of aortocoronary vein graft lesions with membrane-covered stents -: A multicenter surveillance trial [J].
Baldus, S ;
Köster, R ;
Elsner, M ;
Walter, DH ;
Arnold, R ;
Auch-Schwelk, W ;
Berger, J ;
Rau, M ;
Meinertz, T ;
Zeiher, AM ;
Hamm, CW .
CIRCULATION, 2000, 102 (17) :2024-2027
[5]  
Bruining N, 1998, CATHETER CARDIO DIAG, V43, P254, DOI 10.1002/(SICI)1097-0304(199803)43:3<254::AID-CCD3>3.0.CO
[6]  
2-8
[7]   THE BIOLOGY OF SAPHENOUS-VEIN GRAFT OCCLUSION - ETIOLOGY AND STRATEGIES FOR PREVENTION [J].
BRYAN, AJ ;
ANGELINI, GD .
CURRENT OPINION IN CARDIOLOGY, 1994, 9 (06) :641-649
[8]   Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention [J].
Chu, WW ;
Rha, SW ;
Kuchulakanti, PK ;
Cheneau, E ;
Torguson, R ;
Pinnow, E ;
Alexieva-Fournadjiev, J ;
Pichard, AD ;
Satler, LF ;
Kent, KM ;
Lindsay, J ;
Waksman, R .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (01) :34-37
[9]   Retrospective image-based gating of intracoronary ultrasound images for improved quantitative analysis: The intelligate method [J].
de Winter, SA ;
Hamers, R ;
Degertekin, M ;
Tanabe, K ;
Lemos, PA ;
Serruys, PW ;
Roelandt, JRTC ;
Bruining, N .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2004, 61 (01) :84-94
[10]   Pathology of restenosis in saphenous bypass grafts after long-term stent implantation [J].
Depre, C ;
Havaux, X ;
Wijns, W .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 110 (03) :378-384